Lantern Pharma Inc. (LTRN) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Lantern Pharma Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary RADR® artificial intelligence platform to identify drug candidates and patient populations for targeted oncology therapies. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of November 1, 2024, there were 10,784,725 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4,505,697) | $(3,161,450) | $(14,906,013) | $(11,775,613) |
| Loss Per Share (Basic/Diluted) | $(0.42) | $(0.29) | $(1.39) | $(1.08) |
| Operating Expenses | $5,179,576 | $3,523,621 | $16,320,038 | $13,000,186 |
| Research & Development (R&D) | $3,716,646 | $2,209,894 | $11,856,169 | $8,321,058 |
| General & Administrative (G&A) | $1,462,930 | $1,313,727 | $4,463,869 | $4,679,128 |
| Cash & Cash Equivalents (End of Period) | $8,102,819 (Sep 30, 2024) vs $21,937,749 (Dec 31, 2023) |
|||
| Marketable Securities | ||||
| Total Liquidity (Cash + Securities) | $28,053,765 (Sep 30, 2024) | |||
| Working Capital | $26,320,000 (Sep 30, 2024) | |||
| Debt | No long-term debt outstanding. |
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses increased by 68% ($1.5M) in Q3 2024 compared to Q3 2023, driven by increased research study and material costs ($1.2M) for clinical trials, higher salaries, and consulting fees. Year-to-date R&D increased 42% ($3.5M).
- Net Loss Expansion: Net loss for Q3 2024 increased to $4.5M from $3.2M in the prior year quarter. YTD net loss increased to $14.9M from $11.8M.
- Cash Burn: Net cash used in operating activities for the nine months ended September 30, 2024, was $13.8M, an increase from $11.0M in the same period in 2023. Cash and cash equivalents decreased by approximately $13.8M during the nine-month period.
- Other Income: Other income, net, increased significantly in Q3 2024 ($483k vs $116k) primarily due to net appreciation in the fair value of mutual funds and common stock (including Actuate Therapeutics shares) and foreign currency remeasurement gains.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($28.1M total) will fund operations for at least 12 months from the filing date. The company plans to explore periodic capital raises and grant funding.
- Clinical Pipeline:
- LP-300: Advancing in the Phase 2 Harmonic™ trial for never-smokers with advanced non-small cell lung cancer (NSCLC).
- LP-184 (STAR-001): Advancing in Phase 1 for solid tumors and CNS cancers (via subsidiary Starlight Therapeutics).
- LP-284: Advancing in Phase 1 for hematological cancers.
- ADC Program: Preclinical optimization of antibody-drug conjugates.
- Risks: The company has no revenue and expects to incur significant losses for the foreseeable future. Risks include the failure of clinical trials, inability to secure additional funding, and reliance on the RADR® platform's efficacy. Substantially all cash balances are in excess of FDIC insurance limits.
- Unusual Items: The company recognized a gain on the fair value of Actuate Therapeutics common stock ($103k) following Actuate's IPO in August 2024. This stock is subject to a 90-day lock-up period.
Investor Verification Checklist
- Cash Runway: Verify the $28.1M liquidity position against the projected burn rate to confirm the 12-month runway assertion.
- Clinical Milestones: Monitor enrollment and data readouts for the LP-300 Phase 2 Harmonic™ trial and LP-184 Phase 1 trial.
- Capital Needs: Assess the likelihood and terms of future equity raises or debt financing required to sustain operations beyond the 12-month horizon.
- Investment Valuation: Review the unrealized losses on marketable securities ($339k total unrealized loss) and the impact of interest rate changes on the portfolio.
- Actuate Stake: Track the 90-day lock-up expiration for the 13,889 shares of Actuate Therapeutics stock held by Lantern.